• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    50.23 +0.33 (+0.66%)
    Streaming Delayed Price Updated: 10:42 AM EDT, May 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    News headline image
    The Best Stocks to Invest $3,000 In Right Now ↗
    Not every high-potential name costs a fortune to step into. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗
    CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple... 
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
    The biotech's innovative platform could pay off. 
    Via The Motley Fool
    News headline image
    Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
    The market wasn't impressed by its latest quarterly update. 
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
    These companies are leaders in their fields. 
    Via The Motley Fool
    News headline image
    What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
    The biotech's candidate may treat a great number of illnesses that have one thing in common. 
    Via The Motley Fool
    News headline image
    Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
    This particular player has seen its yield rise in recent years. 
    Via The Motley Fool
    News headline image
    3 Growth Stocks That Could Generate 10X Returns ↗
    These stocks come with risk, but they also have some exciting long-term growth opportunities. 
    Via The Motley Fool
    Topics Cannabis Law Enforcement
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
    We'll know more about the company's medium-term prospects by the end of the year. 
    Via The Motley Fool
    News headline image
    2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
    The company's strong cash position gives investors confidence in the gene-editing stock. 
    Via The Motley Fool
    News headline image
    This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗
    Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years. 
    Via The Motley Fool
    News headline image
    Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
    With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
    The gene-editing stock has been in a tailspin of late. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
    As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant... 
    Via Finterra
    Topics Intellectual Property
    News headline image
    Is CRISPR Therapeutics Stock a Buy Now? ↗
    We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates. 
    Via The Motley Fool
    News headline image
    3 Monster Stocks to Hold for the Next 10 Years ↗
    They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗
    Current shareholders were thrown an unexpected curveball that they actually should have been expecting. 
    Via The Motley Fool
    News headline image
    Why Is CRSP Stock Falling Pre-Market Today? ↗
    The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031. 
    Via Stocktwits
    News headline image
    RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗
    The firm believes the new lineup could significantly expand Rivian's addressable EV market. 
    Via Stocktwits
    Topics Electric Vehicles
    News headline image
    Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
    These two biotechs have a lot in common. Their differences are even more pronounced. 
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
    CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential. 
    Via The Motley Fool
    News headline image
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
    Could these three stocks be Cathie Wood's next big winners? 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? ↗
    The past few years have been challenging for the biotech. 
    Via The Motley Fool
    News headline image
    The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
    Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
    These biotech companies have catalysts ahead. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
    Via MarketBeat
    News headline image
    Should You Buy Shares of CRISPR Therapeutics in February? ↗
    The company could finally be ready to deliver on years of promise. 
    Via The Motley Fool
    News headline image
    The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
    2026 could be a big year for this company. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
    A sales partner offered a ray of hope that this company couldn't for itself. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    36 37 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.